Beam Therapeutics (BEAM) - Company Cash Volume

BEAM (beamtx.com) - company brandmark

Free cash flow demonstrates the financial resilience of Beam Therapeutics Inc. (BEAM), where the current figure stands at 1.04. Liquidity trends are critical, as the absence of commercial products leaves the company dependent on external financing and laboratory breakthroughs. Meanwhile, the business relies on licensing agreements with industry behemoths to advance high-precision genome editing, combining third-party manufacturing with the development of its own plant.

BEAM - Beam Therapeutics Corp Company Cash on Hand over the range 07/04/2022 - 11/21/2026

Financial and market metric breakdowns for Beam Therapeutics (BEAM)

Basic company analysis:BEAM Beam Therapeutics
Product sample of beamtx.com

Beam Therapeutics Inc. (BEAM) holds a leading position in the development of precision DNA editing, where liquidity is critical for funding the costly clinical trials of its "genetic eraser." By analyzing the cash reserve metric, an investor assesses the actual burn rate and the business's autonomy horizon, which allows for forecasting the risk of default or the necessity of a secondary offering prior to product commercialization.

Who Beam Therapeutics Inc. competes with

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|SRPT (Sarepta Therapeutics) - Company Cash Volume|Company Cash on Hand Twist Bioscience Inc (TWST)|Company Cash Volume TXG|Company Liquid Assets Intellia|Stoke - Company Cash on Hand|BLFS: Company Cash and Cash Equivalents|Wave Life Sciences Corp - Company Cash Volume|Maze Therapeutics, Inc. (MAZE) - Company Cash on Hand|Sionna Therapeutics Inc (SION) - Company Cash Funds|Company Cash on Hand Prime Medicine Corp|Company Cash Funds tayshagtx.com|QURE - Company Cash Position|Company Cash on Hand MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Company Cash Position|Company Cash Volume SLDB (Solid Biosciences Inc.)|Company Cash Balance OCGN|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume